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A B S T R A C T
EuroFlow Quality Assessment was designed to provide a feedback on the quality of the standardization effort in
executing the EuroFlow protocols for sample preparation and instrument setup. It was first beta-tested by the
members of the EuroFlow consortium internally (2010−2013) and opened to the external participants from
2015 onwards. The goal of participation in the EuroFlow QA is to evaluate whether the technical quality of the
data generated by the laboratory is comparable to the data of the EuroFlow members and thus if a non-EuroFlow
member participant can use the EuroFlow reference sample database for his own patient evaluation. Also it
assesses whether data are sufficiently standardized for automated population gating and alarm notification. By
spring 2018, a total 87 laboratories from 32 countries on five continents have registered for the EuroFlow QA
program. We evaluated 163 results of 2015–2016 QA rounds, where we noted clear improvement in the score of
first-time participants (median score of 91% correct) when they participated second time or later (median score
of 94% correct, p=0,017), which was comparable to EuroFlow member scores (median score of 97% correct).
Among frequent mistakes, we found non-adherence to the EuroFlow protocols (improper reagent used), im-
proper gating and some compensation issues. In summary, we show that EuroFlow QA has a positive impact on
improvement of standardized data quality of non-member laboratories adhering to the EuroFlow standard op-
erating procedures and reagent panels.
1. Introduction
The EuroFlow consortium has developed a series of standardized
protocols for diagnostic use (van Dongen et al., 2012) and for mon-
itoring treatment response (Theunissen et al., 2016; Flores-Montero
et al., 2017a) by flow cytometry. These protocols have been adopted in
multiple diagnostic laboratories. 87 laboratories from 32 countries on
five continents have registered for the EuroFlow QA program, which
means they are actively using the EuroFlow protocols and trying to
improve. The interest in the protocols is also reflected by the fact that
around 16,000 documents have been downloaded by ~1750 institutes
in 3 years-time from the euroflow.org website. Patients' samples ac-
quired in this standardized fashion can be directly compared to each
other, and carefully annotated measurements can be compiled in a data
base (Pedreira et al., 2013; Pedreira et al., 2008) and used as a
reference for evaluation of new cases (Lhermitte et al., 2018; Costa
et al., 2010). Overall, 3124 reference samples acquired in 15 EuroFlow
laboratories were uploaded by January 2017 to the EuroFlow server to
be used for the construction of the EuroFlow databases. Standardization
of the instrument set-up and panels of reagents, together with a uniform
approach for data analysis is instrumental to make comparisons of in-
dividual samples to the common database (Kalina et al., 2012). Quality
of the measured data is evaluated with EuroFlow Quality Assessment
scheme (Kalina et al., 2015). In this approach, obtaining virtually
identical or highly similar median fluorescence intensity (MFI) values
for a particular cell subset labeled with a given fluorescent reagent is
considered a standardization endpoint. The EuroFlow Quality Assess-
ment (QA) program was launched in 2010 for the members of the
EuroFlow consortium to ensure their adherence to the agreed stan-
dardization. In 2014, the results of the first three years of the QA
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program were summarized (Kalina et al., 2015) and in 2015 the
EuroFlow QA was opened to participants outside the EuroFlow con-
sortium. The EuroFlow QA was build to specifically test the quality of
the execution of the QA modified Lymphoid Screening Tube (LST-QA)
measurement, where locally drawn healthy volunteers' peripheral
blood is used as a model. The guidance for the participants as well as
reporting of the results is organized via a dedicated EuroFlow QA
website and QA rounds are organized twice per year. The participants
choose to use either the originally published single reagents or they can
use a centrally distributed lyophilized mixture of reagents (both var-
iants were shown to yield comparable results (van der Velden et al.,
2017) and participants should choose the approach, which is more
Fig. 1. Score of EuroFlow QA in 2015–2016 for A) EuroFlow members (blue), B) first participation of non-EuroFlow members (orange) and C) repeated participations
of non-EuroFlow members (brown). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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resembling their routine practice) (Kalina et al., 2015). The evaluation
of the QA-test is based on the distance of the measured MFI of pre-
defined lymphocyte subsets labeled with the LST-QA reagents from the
expected MFI established during the original standardization process. In
contrast, the EuroFlow QA does not test the ability of the laboratory to
perform a clinical interpretation (establish a diagnostic conclusion).
Participants receive QA certificates with an overview of their results for
all tested parameters. Whenever found, values out of range are high-
lighted. Participants also receive a graphical representation of the re-
sults highlighting the values measured by their laboratory among all
laboratories participating in a given round. A summary of the issues
encountered and their possible causes is circulated to all participants at
the end of each round. In addition, the EuroFlow QA participants'
meetings (first organized in Aarau, Switzerland, in November 2016)
serve as a platform for education and troubleshooting.
Here we report on the EuroFlow QA program results and both the
most frequent problems encountered among the participants in the
EuroFlow QA program and the lessons learned from them.
2. Methods
2.1. Data acquisition, participants and instruments
Detailed execution of the EuroFlow QA has been described earlier
(Kalina et al., 2015). The EuroFlow QA scheme was opened to non-
EuroFlow member laboratories in 2015. By the end of 2016, a total 65
laboratories from 30 different countries in five continents have regis-
tered for the QA program (Supplementary Table 1) and 64 have been
evaluated; the remaining laboratory did not submit QA results. Fifteen
of them were EuroFlow member laboratories and fifty were non-
members. Thus, out of 91 reports submitted by non-members, 46 were
from first time participants, 45 were from repeated QA. 72 reports were
from EuroFlow laboratories (three laboratories reported two sets of
measurements for two different instruments each). In total 489 files
have been evaluated (163 QA sets of three samples each). The majority
of users acquired their data on the BD FACS Canto II (BD Biosciences,
San Jose, CA) instruments, while two participating laboratories used
the Navios instrument (Beckman Coulter, Brea, CA).
3. Data analysis
Analysis of each file was done according to the QA instructions by
each reporting analyst and MFI values were entered into the EuroFlow
QA website interface; in parallel the gated flow cytometry standard
(FCS) data files analyzed with the Infinicyt software (Cytognos SL,
Salamanca, Spain) “.cyt” were uploaded to the EuroFlow QA server.
Meta-analysis of all reports and its graphical representations were done
in Microsoft Excel for Mac 2011 (Microsoft Corporation, Redmond,
Washington, USA).
4. Results
A comparison of the overall scores of the EuroFlow members and
non- EuroFlow members is shown in Fig. 1. Overall score is calculated
as a sum of p-score points falling into acceptable range of Dmax. P-score
evaluates a deviation from expected (ideal) Median Fluorescence In-
tensity and is derived from the 90th (Kappa and Lambda) and 95th
percentiles (other markers), thus it is expected that 90% of p-score
values should fall within the acceptable range. The results of the ex-
perienced EuroFlow laboratories were close to perfect, with median
score 97% (76%–100%; 10th–90th percentile). When only the first-time
participants (non-EuroFlow members) were evaluated, they scored at
median overall score of 91% (76%–100%). An improvement (p= .017)
was achieved in the repeated reports (second and later QA rounds),
where the non-members scored close to the EuroFlow members with
median score of 94% (85%–100%). Of note, while the majority of users
acquired their data on the BD FACSCanto II instruments, two partici-
pating laboratories used the Navios instrument successfully, confirming
that the standardized approach can be taken across instruments of
different brands without compromising the quality as described by
Kalina et al. in this issue (Nováková et al., 2017), whenever the Euro-
Flow standard operating procedures (SOPs) and the EuroFlow re-
commended reference (or alternative) reagents are used.
For each parameter, we also analyzed the frequency of failure
(Table 1). The most frequently failed parameter was CD81 APC-C750
(20.2%), followed by CD56 PE on CD56 bright NK cells (16.1%) and
CD4 Pacific Blue (12.9%). Most CD81 failures were due to protocol non-
adherence, where participants stained the sample with CD38 APCC750
instead (this is the only reagent different between the EuroFlow LST
tube and the EuroFlow LST-QA tube). In turn, failure for the CD56 PE
parameter on CD56-bright NK cells was typically due to improper
gating. Since 82% of results were submitted together with their gated
files for QA evaluation (recommended but not required), we could
backtrack that instead of gating the CD56-bright cells they gated all
CD56-positive cells. In the remaining cases we were not able to track
down the reasons for the QA failures.
An example of how well the LST-QA tube with a perfect score
matches a reference file (measured by different personnel, at a different
site, on a different instrument, using different healthy adult normal
peripheral blood samples) is shown in Fig. 2A. This is compared to a file
with a score of 70% overall score in Fig. 2B.
5. Discussion
The EuroFlow QA program was successfully launched to public and
it was well adopted by the laboratory diagnostics community. The same
QA approach (using a complete EuroFlow LST tube) was adopted by the
Swiss Cytometry Society for inter-laboratory training and evaluation
(see Glier et al. in this issue (Glier et al., 2017)). Our experience so far
shows that the EuroFlow QA program (Kalina et al., 2015) is properly
set up, testing relevant endpoints and providing a feedback on the most
frequent issues with the execution of the EuroFlow protocols. The
consistency of signal intensity enables to discern the complex patterns,
which form the basis for the comparison of individual samples to the
EuroFlow database of known well-defined reference samples (Flores-
Table 1
Frequency of tests failing per reagent included in the LST-QA combina-
tion.
Reagent Out of range results
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Fig. 2. Example of a perfectly correct result (Panel A) and a result with a score of 70% (Panel B). Results are shown as dots and expected patterns are depicted as
reference image contours. Of note in panel B, CD4, CD8, CD19 and CD5 have lower intensity than expected).
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Montero et al. in this issue (Lhermitte et al., 2018; Flores-Montero et al.,
2017b)).
An essential component of the standardization of fluorescence in-
tensity measurements is the reproducibility of the performance of an-
tibody conjugates (Böttcher et al., 2017; Blanco et al., 2017). EuroFlow
has built a list of reagents that perform equally well as the original
reagents in a series of standardized measurements. Those are the so-
called “EuroFlow alternative reagents” and their list is available at the
www.euroflow.org website. To be included in the list, the alternative
reagents had to show a similar staining pattern (in an overlay with the
original reagent) and a median fluorescence intensity that does not
differ by more than 30% from the original reagent when used on the
same sample as a single reagent and/or when tested in the respective
EuroFlow antibody combination in liquid or dried format (van der
Velden et al., 2017). Testing was performed independently by three
EuroFlow laboratories (in parallel) as a paid service to the reagents'
manufacturers, and only valid alternative reagents being disclosed.
While our data show that the alternative reagents can indeed perform
equally well (at the time of testing), it is out of the control of EuroFlow
or the end-user, whether a particular manufacturer maintains the re-
producibility (to provide the same MFI in a standardized test) in dif-
ferent reagents' lots (Böttcher et al., 2017). Manufacturers often declare
a Quality Control (QC) was performed, however there are no publically
available guidelines or parameters that would allow the user to judge,
whether the expected reproducibility of signal was achieved (and how
it was measured). In this issue, Böttcher et al. (Böttcher et al., 2017),
report on a lot-to-lot signal intensity evaluation using antibody capture
beads, where the failure to provide a signal comparable to the previous
lot ranged from 0% to 37.5%, for different fluorochromes and manu-
facturers. Thus, it is essential for standardized clinical investigations
that the antibody producers perform a lot-to-lot intensity evaluation of
their reagents and quantify and declare the reproducibility that is
guaranteed by their QC process. In turn, it is implicitly stated here that,
a given reference MFI value and not a staining intensity brighter than a
given threshold MFI value is to be used as the criteria to define alter-
native reagents to the EuroFlow reference reagents.
Additional sources of differences we have observed were related to
an improper execution of the sample preparation SOP (insufficient
washing off the plasma) that led to a low labeling of B cells by anti-
bodies against immunoglobulin (Ig) light chains (anti-lambda and anti-
kappa Ig light chain reagents). In those samples, B cells had to compete
for the labeling reagent with the abundant immunoglobulins in the
unwashed plasma. Frequently, we noted issues that are caused by non-
adherence to the protocol. A striking example is the usage of reagents
that have never been tested and validated by the EuroFlow consortium
and consequently, that have never been approved neither as reference
nor as alternative reagents, and which do not perform similar to the
reference EuroFlow reagents. On one hand, the degree of non-ad-
herence is worrisome in clinical laboratories but at the same time this
gets often corrected after receiving the feedback from the QA and re-
training. As seen in other studies, we also point to improper gating
strategies as a relatively frequent source of error (Finak et al., 2016;
Whitby et al., 2012).
An imperfect compensation was another frequently found error.
While the QA is not designed to formally test compensation issues, gross
abnormalities can be easily recognized. Since compensation values are
predictable in systems with fixed optical filters, standardized instru-
ment setup and standardized panels of stable reagents, we expect that
software solutions will be developed to reduce major compensation
errors. Before this is achieved, a good practice in performing compen-
sation experiments must be ensured through proper training.
Notably, because the QA program is based on a relatively stable
expression of the evaluated surface markers, with very low variation
among healthy individuals, there is no need to send out a reference
sample. This not only makes it affordable at distant locations, but also
logistically feasible across the globe, even in resource poor countries or
countries with difficult custom procedures.
It should be stressed again that while the EuroFlow QA program
tests the sample preparation, cytometer setting, aquisition and analysis,
it does not test the proper diagnostic interpretation. Thus, it cannot
replace the established QA programs required for ISO 15189 accred-
itation. However, this QA process together with the EuroFlow database
and automated data analysis will be a significant aid to achieve also
proper, robust and reproducible diagnoses.
Importantly, the EuroFlow QA involves a face-to-face participant
meeting during which those issues found are reviewed with the parti-
cipants, and offers retraining and education. The first educational
meeting was organized in Aarau, Switzerland (November 2016), fol-
lowed by Leiden (November 2017) and it will be repeated annually.
In conclusion, the EuroFlow QA program is well established and has
proven its value for improving the execution of the EuroFlow protocols.
Half of the non-EuroFlow laboratories scored well the first time they
participated in the program and a further improvement could be clearly
seen in subsequent rounds reaching scores comparable to the EuroFlow
member laboratories.
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